

AbbVie Inc.
Form 4
April 30, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
GONZALEZ RICHARD A

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO, IL 60064

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
AbbVie Inc. [ABBV]

3. Date of Earliest Transaction
(Month/Day/Year)
04/28/2015

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☐ Director ☐ 10% Owner
☒ Officer (give title below) ☐ Other (specify below)

Chairman of the Board and CEO

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock, \$0.01 par value	04/28/2015		S	4,400	D \$ 64.74	550,260	D
Common stock, \$0.01 par value	04/28/2015		S	506	D \$ 64.745	549,754	D
Common stock, \$0.01 par value	04/28/2015		S	100	D \$ 64.7475	549,654	D

Edgar Filing: AbbVie Inc. - Form 4

Common stock, \$0.01 par value	04/28/2015	S	2,500	D	\$ 64.75	547,154	D
Common stock, \$0.01 par value	04/28/2015	S	900	D	\$ 64.76	546,254	D
Common stock, \$0.01 par value	04/28/2015	S	100	D	\$ 64.77	546,154	D
Common stock, \$0.01 par value	04/28/2015	S	300	D	\$ 64.79	545,854	D
Common stock, \$0.01 par value	04/28/2015	S	100	D	\$ 64.8	545,754	D
Common stock, \$0.01 par value	04/28/2015	S	1,300	D	\$ 64.81	544,454	D
Common stock, \$0.01 par value	04/28/2015	S	1,400	D	\$ 64.815	543,054	D
Common stock, \$0.01 par value	04/28/2015	S	2,500	D	\$ 64.82	540,554	D
Common stock, \$0.01 par value	04/28/2015	S	3,900	D	\$ 64.83	536,654	D
Common stock, \$0.01 par value	04/28/2015	S	600	D	\$ 64.835	536,054	D
Common stock, \$0.01 par value	04/28/2015	S	2,100	D	\$ 64.84	533,954	D
	04/28/2015	S	400	D		533,554	D

Edgar Filing: AbbVie Inc. - Form 4

Common stock, \$0.01 par value					\$ 64.8425		
Common stock, \$0.01 par value	04/28/2015	S	1,200	D	\$ 64.845	532,354	D
Common stock, \$0.01 par value	04/28/2015	S	14,488	D	\$ 64.85	517,866	D
Common stock, \$0.01 par value	04/28/2015	S	300	D	\$ 64.8525	517,566	D
Common stock, \$0.01 par value	04/28/2015	S	1,869	D	\$ 64.855	515,697	D
Common stock, \$0.01 par value	04/28/2015	S	800	D	\$ 64.8575	514,897	D
Common stock, \$0.01 par value	04/28/2015	S	14,000	D	\$ 64.86	500,897	D
Common stock, \$0.01 par value	04/28/2015	S	3,100	D	\$ 64.865	497,797	D
Common stock, \$0.01 par value	04/28/2015	S	100	D	\$ 64.8675	497,697	D
Common stock, \$0.01 par value	04/08/2015	S	1,300	D	\$ 64.87	496,397	D
Common stock, \$0.01 par value	04/28/2015	S	1,000	D	\$ 64.875	495,397	D
	04/28/2015	S	1,800	D	\$ 64.88	493,597	D

Common
stock,
\$0.01 par
value

Common
stock,
\$0.01 par
value

Common
stock,
\$0.01 par
value

04/28/2015

S

200

D

\$ 64.8825

493,397

D

04/28/2015

S

2,969

D

\$ 64.89

490,428

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Transaction (Instr. 10)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
GONZALEZ RICHARD A 1 N. WAUKEGAN ROAD NORTH CHICAGO, IL 60064	X		Chairman of the Board and CEO	

Signatures

Steven L. Scrogham, attorney-in-fact for Richard A.
Gonzalez

04/30/2015

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Remarks:

Form 2 of 3. These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.